Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

被引:64
|
作者
Singh, M
Li, XM
Wang, HY
McGee, JP
Zamb, T
Koff, W
Wang, CY
OHagan, DT
机构
[1] UNITED BIOMED INC,HAUPPAUGE,NY 11788
[2] HANNAH RES INST,CORE TECHNOL LTD,AYR KA6 5HL,SCOTLAND
关键词
D O I
10.1128/IAI.65.5.1716-1721.1997
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tetanus toxoid (TT) was encapsulated in microparticles prepared from polylactide-co-glycolide polymers by a solvent-evaporation technique. Combinations of small- and large-sized microparticles with controlled-release characteristics were used to immunize Sprague-Dawley rats, and the antibody responses were monitored for 1 year. For comparison, control groups of rats were immunized at 0, 1, and 2 months with TT adsorbed to alum. The antibody responses generated by the TT entrapped in microparticles were comparable to those generated by TT adsorbed to alum in control groups from 32 weeks onwards. Microparticles with a single entrapped antigen (TT) induced better antibody responses than microparticles with two antigens (TT and diphtheria toroid) entrapped simultaneously. A combination vaccine consisting of TT adsorbed to alum and also entrapped in microparticles gave the best antibody responses. In an inhibition assay designed to determine the relative levels of binding of antisera to the antigens, the sera from the microparticle- and the alum-immunized animals showed comparable levels of binding. In addition, in a passive-challenge study with mice, TT adsorbed to alum and TT entrapped in microparticles provided equal levels of protection against a lethal challenge with tetanus toxin. An intradermal-challenge study was also performed with rabbits, which showed similar levels of protection in sera from alum- and microparticle-immunized animals at 4, 12, and 32 weeks after immunization.
引用
收藏
页码:1716 / 1721
页数:6
相关论文
共 32 条
  • [31] Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
    Lioznov, Dmitry
    Amosova, Irina A.
    Sheetikov, Savely
    Zornikova, Ksenia
    Serdyuk, Yana
    Efimov, Grigory
    Tsyferov, Mikhail
    Khmelevskii, Mikhail
    Afanasiev, Andrei
    Khomyakova, Nadezhda
    Zubkov, Dmitry
    Tikhonov, Anton
    Zhu, Tao
    Barreto, Luis
    Dzutseva, Vitalina
    PLOS ONE, 2023, 18 (03):
  • [32] Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
    Robbins, Jonathan A.
    Tait, Dereck
    Huang, Qinlei
    Dubey, Sheri
    Crumley, Tami
    Cote, Josee
    Luk, Julie
    Sachs, Jeffrey R.
    Rutkowski, Kathryn
    Park, Harriet
    Schwab, Robert
    Howitt, William Joseph
    Rondon, Juan Carlos
    Hernandez-Illas, Martha
    O'Reilly, Terry
    Smith, William
    Simon, Jakub
    Hardalo, Cathy
    Zhao, Xuemei
    Wnek, Richard
    Cope, Alethea
    Lai, Eseng
    Annunziato, Paula
    Guris, Dalya
    Stoch, S. Aubrey
    EBIOMEDICINE, 2022, 82